Moximed® International, Inc: Dedicated to Improving the Standard of Care for Patients with Osteoarthritis
Osteoarthritis (OA), the most common form of arthritis, affects an estimated 35 - 40 million Europeans.1 Also known as degenerative joint disease, OA leads to a breakdown of a joint's cartilage and often results in joint pain and loss of motion. OA commonly affects the knees, hips, hands, or back.
The goals of OA treatment include minimizing joint pain, restoring normal activity levels, and slowing disease progression. However, many current therapies are either ineffective or involve highly invasive, joint modifying procedures. Moximed is initially focused on developing minimally invasive, joint sparing solutions for patients with knee osteoarthritis.
Researchers recognize that excessive forces acting on a joint contribute to the onset and progression of OA.2, 3 In response, Moximed created The KineSpring® Knee Implant System, a revolutionary new device designed to absorb excess weight that is normally supported by the knee joint.
The KineSpring System has been evaluated by leading surgeons in multiple, international clinical studies. It has been granted CE Mark and is currently available for sale in select centers in Europe and Australia.
1. Helmick, Arth Rheum; Jan 2008; 58(1); 26-35.
2. Radin EL. Who gets osteoarthritis and why? An update. J Rheumatol 2005; 32:1136-8.
3. Block JA, Shakoor N. The biomechanics of osteoarthritis: implications for therapy. Curr Rheumatol Rep 2009; 11: 15-22.